AlphaQuest LLC Grows Stake in Envista Holdings Corporation $NVST

AlphaQuest LLC increased its stake in Envista Holdings Corporation (NYSE:NVST) by 60.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,717 shares of the company’s stock after acquiring an additional 16,162 shares during the period. AlphaQuest LLC’s holdings in Envista were worth $835,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Parallel Advisors LLC lifted its stake in Envista by 100.1% in the second quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock worth $55,000 after purchasing an additional 1,397 shares during the last quarter. FourThought Financial Partners LLC bought a new stake in Envista in the first quarter worth about $180,000. Vestcor Inc bought a new stake in Envista in the first quarter worth about $211,000. Pallas Capital Advisors LLC bought a new stake in Envista in the second quarter worth about $300,000. Finally, Aigen Investment Management LP bought a new stake in Envista in the first quarter worth about $274,000.

Analysts Set New Price Targets

Several brokerages have issued reports on NVST. Piper Sandler raised their price objective on shares of Envista from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, August 1st. Mizuho raised their price objective on shares of Envista from $15.00 to $18.00 and gave the stock an “underperform” rating in a research note on Friday, August 1st. Wall Street Zen lowered Envista from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 30th. UBS Group boosted their price target on Envista from $18.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, July 29th. Finally, Wells Fargo & Company boosted their price target on Envista from $17.00 to $19.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $21.08.

Envista Stock Performance

Shares of NYSE:NVST opened at $20.40 on Monday. The company has a market capitalization of $3.39 billion, a price-to-earnings ratio of 63.75, a price-to-earnings-growth ratio of 1.09 and a beta of 1.01. Envista Holdings Corporation has a 52 week low of $14.22 and a 52 week high of $23.00. The company has a quick ratio of 2.08, a current ratio of 2.44 and a debt-to-equity ratio of 0.46. The firm has a 50 day moving average of $20.59 and a 200 day moving average of $19.23.

Envista (NYSE:NVST) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. The company had revenue of $682.10 million during the quarter, compared to the consensus estimate of $638.21 million. Envista had a net margin of 2.11% and a return on equity of 4.84%. Envista’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.11 earnings per share. Envista has set its FY 2025 guidance at 1.050-1.15 EPS. On average, sell-side analysts predict that Envista Holdings Corporation will post 1 earnings per share for the current fiscal year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.